Leads Biolabs

CompanyChina

Leads Biolabs develops 2 assets. Mostly antibody acting on CD274 and TNFRSF9; based in China.

2
Assets
Furthest stage: Not known
Raised: $189M; 0
Trials: 0
Signals

Pipeline

2

LBL-034
Stage not known, Antibody
Opamtistomig
Bispecific antibody that blocks PD-L1 and activates 4-1BB to enhance antitumor immune responses.
Stage not known, Antibody, CD274, TNFRSF9

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms2
Funding rounds and grants1
Similar companies6